Supercharge Your Innovation With Domain-Expert AI Agents!

Fibrin glue composite system loaded with cisplatin

A technology of fibrin glue and fibrinogen, applied in the direction of drug combination, non-active ingredients of polymer compounds, medical preparations containing active ingredients, etc., can solve the problems of non-targeted distribution, potential safety hazards, toxic and side effects, etc. To achieve the effect of inhibiting proliferation, inhibiting recurrence, and less toxic and side effects

Active Publication Date: 2020-12-08
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the distribution of CDDP in the body is non-targeting, which may lead to adverse reactions, the most common being nephrotoxicity, neurotoxicity, ototoxicity, and bone marrow suppression. There are still potential safety hazards in this treatment mode of systemic administration.
Clinical studies have found that patients treated with CDDP and radiotherapy have more serious side effects than patients treated alone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fibrin glue composite system loaded with cisplatin
  • Fibrin glue composite system loaded with cisplatin
  • Fibrin glue composite system loaded with cisplatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1: Preparation of fibrin glue (Fibrin gel)

[0039] 1. Preparation of thrombin solution

[0040] Thrombin was purchased from Dalian Meilun Biotechnology Co., Ltd., product number MB1368, molecular weight 37kD, CASNo.9002-0404.

[0041] Add thrombin to 40mmol / L calcium chloride aqueous solution to dissolve, prepare a thrombin solution with a concentration of 100 units / mL, and store at -20°C.

[0042] 2. Preparation of fibrinogen solution

[0043] Fibrinogen was purchased from Dalian Meilun Biotechnology Co., Ltd., product number MB5809, molecular weight 340kDa, CAS No.9001-32-5.

[0044] The fibrinogen was dissolved in 0.9% physiological saline to prepare a fibrinogen solution with a concentration of 10 mg / mL, and stored at -20°C.

[0045] 3. Preparation of fibrin glue

[0046] The above fibrinogen solution and thrombin solution were mixed according to the volume ratio of 9:1 to form fibrin glue.

Embodiment 2

[0047] Embodiment 2: Preparation of cisplatin / fibrin glue (CDDP / Fibrin gel) composite system

[0048] 1. Preparation of thrombin solution

[0049] Using the same method as in Step 1 of Example 1, a thrombin solution with a concentration of 100 units / mL was prepared and stored at -20°C.

[0050] 2. Preparation of fibrinogen solution

[0051] Using the same method as in Step 2 of Example 1, a fibrinogen solution with a concentration of 10 mg / mL was prepared and stored at -20°C.

[0052] 3. Configure CDDP solution

[0053] Cisplatin (CDDP) was purchased from Dalian Meilun Biotechnology Co., Ltd.

[0054] Add CDDP to 0.9% physiological saline to dissolve, prepare a CDDP solution with a concentration of 2 mg / mL, and store at -20°C.

[0055] 4. Preparation of CDDP / Fibringel composite system

[0056] The above-mentioned fibrinogen solution, thrombin solution and CDDP solution were mixed at a volume ratio of 9:1:1 to obtain a CDDP / Fibringel composite system.

Embodiment 3

[0057] Embodiment 3: preparation combined therapy equipment

[0058] The combination therapy equipment of the present invention is composed of two parts: (1) stereotaxic radiotherapy device, (2) drug package. Wherein, the drug package includes the CDDP / Fibringel composite system prepared in Example 2.

[0059] The beneficial effect of the preparation of the present invention is demonstrated by the following experimental examples.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a fibrin glue composite system loaded with cisplatin. and specifically provides a fibrin glue, which is prepared from thrombin solution and fibrinogen solution as raw materials. The invention also provides a cisplatin / fibrin glue composite system which is prepared by taking a cisplatin solution, a thrombin solution and a fibrinogen solution as raw materials. The cisplatin / fibrin glue composite system has an excellent inhibition effect on postoperative growth of breast cancer, and has a good application prospect in preparation of drugs for treating tumors. More importantly, the cisplatin / fibrin glue composite system is combined with radiotherapy to play a synergistic interaction role in inhibiting recurrence of locally advanced breast cancer, and can more effectively inhibit recurrence of locally advanced breast cancer. Therefore, combined use of the fibrin glue composite system loaded with cisplatin with a radiotherapy device has broad application prospects inpreparing combined treatment equipment for treating tumors (especially locally advanced tumors).

Description

technical field [0001] The invention belongs to the field of material drug carriers, and in particular relates to a fibrin glue composite system loaded with cisplatin, and the use of the system in combination with a radiotherapy device in preparing equipment for treating tumors. Background technique [0002] Breast cancer is one of the most common malignant tumors in women, and has become the main cause of death for female malignant tumor patients worldwide. About 1.4 million people are diagnosed with breast cancer every year, and its incidence is increasing year by year, seriously threatening women's health. Among them, locally advanced breast cancer represents a group of relatively heterogeneous tumors, mainly referring to the primary lesion larger than 5 cm, extensive infiltration in the breast or adhesion and fixation of the skin and chest wall or / and regional lymph node metastasis, and the clinical stage is stage III A type of breast cancer with a poor prognosis. In re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/42A61K33/243A61P35/00
CPCA61K33/243A61K47/42A61P35/00A61P15/14A61N5/1001A61K9/06
Inventor 杨茜
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com